While this is an amazing achievement, the @gsk vaccines is only focused on preventing #RSV for older adults. @Codagenix is developing an #intranasal #vaccine for #pediatrics

Dr. Jeffrey Fu, CBO, Codagenix, describes what is needed in next-generation COVID vaccines. Our vaccine program strives address these factors as a live-attenuated, intranasal vaccine that induces an antibody and cell-mediated immunity (CMI). Learn more: codagenix.com

Did you know? RSV poses a significant risk to children; more than half of RSV deaths occur in children ages 6 months and older. Learn more about our work to develop an RSV vaccine for children: codagenix.com

Our live-attenuated #vaccines leverage proven manufacturing methods for widespread access and delivery. Learn more: codagenix.com/approach/

At Codagenix, we're combining cutting-edge AI and #syntheticbiology to create safer, more effective live-attenuated #virus #vaccines. ️ Learn more: codagenix.com/approach/

Today, on International Day of Women and Girls in Science, we shine a spotlight on the incredible #womeninscience who push the boundaries of science and healthcare, including our very own Director of Preclinical Operations, Keri Wyllie, MPA. Learn more: unesco.org/en/days/women-gir…

#ICYMI – Check this article from @ritarubin on @JAMA_current highlighting Codagenix's work on next-gen #vaccines, incl. those targeting the mucosal immune system via the nose, mimicking the natural infection route. Read the full article: jamanetwork.com/journals/jam…

Curious to learn about the biggest takeaways from #JPM24? Check out this article from @BioSpace that includes updates from Codagenix and many more. Read here: biospace.com/article/jpm-202… #biopharma #biotech #innovation #healthcare

Codagenix CEO, Paul Grint, MD, was interviewed for this @WSJVC feature by Brian Gormley about the recent uptick in #biotech acquisitions. Read here: wsj.com/articles/biotech-acq… #biopharma #innovation #healthcare

#ICYMI - Codagenix was featured in this article from Jon Cohen (@sciencecohen) of @ScienceMagazine about Project NextGen, a U.S. government initiative investing billions in COVID-19 R&D. Read the full article: science.org/content/article/…

Check out this article from @cwillyard in @techreview about the future of needle-free COVID #vaccines, and how Codagenix is among the companies leading the way. technologyreview.com/2023/12…

Thank you @ritarubin and @JAMA_current for highlighting Codagenix's work on next-gen #vaccines, including those targeting the mucosal immune system via the nose, mimicking the natural route of the virus. Read the full article: jamanetwork.com/journals/jam…

This #JPM24, Codagenix’s CEO Paul Grint had the opportunity to speak with Tyler Patchen of @BioSpace about Codagenix’s live attenuated virus approach to #vaccine development. Read the full article: biospace.com/article/jpm-202…

Team Codagenix is attending the 2024 JPMorgan Healthcare Conference in San Francisco, January 8-11. Contact us to schedule a meeting. Learn more about our work: codagenix.com #JPM2024 #JPM24

Dr. Johanna Kaufmann, EVP Oncology and Immunology, will be participating in a panel at the 8th Annual Oncolytic Virotherapy Summit on December 14 at noon ET. We hope to see you there! Learn more: ter.li/41bxld

#DYK that virotherapies have the potential to modulate the tumor microenvironment and trigger immune mechanisms to fight #cancer? At Codagenix, we explore novel #virotherapeutics for #breastcancer and other solid tumors. Learn more about our pipeline: codagenix.com/pipeline/

Thank you @BioWorld for highlighting Codagenix’s @DeptofDefense award of $5.88 million to advance its tetravalent #dengue #vaccine program. Learn more: bioworld.com/articles/702195…

#ICYMI - Codagenix was featured in this article from Jon Cohen (@sciencecohen) of @ScienceMagazine about Project NextGen, a U.S. government initiative investing billions in COVID-19 R&D. Read the full article: science.org/content/article/…

This Thanksgiving, we are #grateful for the incredible team of scientists and researchers at Codagenix who are dedicated to taking on the biggest threats in #infectiousdiseases and #cancer through our powerful codon-modification platform.

Dr. Johanna Kaufmann, EVP Oncology and Immunology, recently spoke to @sabrinaserani of @TargetedOnc about Codagenix’s #oncolytic #virotherapy platform. Watch the full interview: targetedonc.com/view/new-pat…

Today Codagenix announced the presentation of preclinical data for CodaLytic™, a codon-modified virus being developed for #breastcancer #immunovirotherapy, at the @sitcancer 38th Annual Meeting taking place November 1-5, 2023, in San Diego, California. prnewswire.com/news-releases…